Geneoscopy has received FDA approval for an updated, simplified stool collection method for ColoSense®, its RNA-based colorectal cancer (CRC) screening test. The new kit eliminates the need to scrape or divide stool samples—reducing one of the biggest barriers to at-home CRC testing and aiming to boost compliance.
Key highlights:
- FDA-approved as the only RNA-based CRC screening test
- New design removes sample scraping, enhancing patient comfort and reducing errors
- Demonstrated 93% sensitivity for CRC and 45% for advanced adenomas in average-risk adults
- Achieved 100% CRC sensitivity in patients aged 45–49—a growing high-risk group
- Backed by NCCN guidelines and powered by a partnership with Labcorp for broad access
By making at-home screening easier, ColoSense may help close the gap for the 44 million Americans who remain unscreened for CRC.